Visfatin serum concentration is associated with cardiac allograft vasculopathy in heart transplant recipients

Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients...

Full description

Saved in:
Bibliographic Details
Published in:American journal of transplantation 2020-10, Vol.20 (10), p.2857-2866
Main Authors: Szczurek, Wioletta, Gąsior, Mariusz, Skrzypek, Michał, Szyguła‐Jurkiewicz, Bożena
Format: Article
Language:English
Subjects:
Allografts
basic (laboratory) research/science
complication
Female
heart (allograft) function/dysfunction
Heart Diseases
Heart transplantation
Heart Transplantation - adverse effects
heart transplantation/cardiology
Heart transplants
Humans
Inflammation
Limiting factors
Male
Middle Aged
Nicotinamide Phosphoribosyltransferase
Risk Factors
Vascular diseases
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cardiac allograft vasculopathy (CAV) still is one of the most important limiting factors of long‐term survival following heart transplant (HT). This study aimed to investigate the association between proinflammatory adipokine‐visfatin and the incidence of CAV in HT recipients. After HT, 182 patients who had a follow‐up visit at the Transplantation Clinic between 2016 and 2017 were analyzed. The median age was 60.5 years, and 76.4% were men. The incidence of CAV was 54.9%. According to the multivariable proportional hazard regression analysis, visfatin level (1.795 [1.539‐2.094]; P 
ISSN:1600-6135
1600-6143
DOI:10.1111/ajt.15986